XOMA Royalty (XOMA) Free Cash Flow (2010 - 2026)
XOMA Royalty's (XOMA) quarterly Free Cash Flow came in at $6.1 million in Q1 2026, up 178.48% year-on-year from $2.2 million in Q1 2025, and up 211.27% quarter-over-quarter from -$5.5 million in Q4 2025.
XOMA Royalty (XOMA) Free Cash Flow (2010 - 2026) Analysis & Trends
XOMA Royalty has disclosed Free Cash Flow across 17 years of filings, most recently posting $6.1 million for Q1 2026.
- Free Cash Flow for Q1 2026 came in at $6.1 million, up 178.48% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.8 million (up 202.85% YoY), and the FY2025 annual result was $2.9 million, up 120.85% from the prior year.
- Free Cash Flow came in at $6.1 million for Q1 2026 at XOMA Royalty, up from -$5.5 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of $6.5 million in Q2 2025 to a low of -$8.6 million in Q3 2024.
- The 5-year median for Free Cash Flow is -$3.7 million (2022), against an average of -$2.1 million.
- Across the five-year window, Free Cash Flow sank 388.01% in 2023 and surged 178.48% in 2026, its largest moves.
- XOMA Royalty's Free Cash Flow stood at -$3.9 million in 2022, then fell by 0.95% to -$3.9 million in 2023, then grew by 26.0% to -$2.9 million in 2024, then slumped by 89.3% to -$5.5 million in 2025, then surged by 211.27% to $6.1 million in 2026.
- The last three Free Cash Flow figures came in at $6.1 million (Q1 2026), -$5.5 million (Q4 2025), and -$296000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Free Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.29 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 63,220.27 |
| 10 | XOMA Royalty | 5.49 Mn | -60.59 Mn | - | 6.12 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.12 Mn |
| Mar 31, 2026 | 6.12 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Dec 31, 2025 | -5.50 Mn |
| Sep 30, 2025 | -296,000.00 |
| Sep 30, 2025 | -296,000.00 |
| Jun 30, 2025 | 6.47 Mn |
| Jun 30, 2025 | 6.47 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Mar 31, 2025 | 2.20 Mn |
| Dec 31, 2024 | -2.91 Mn |
| Dec 31, 2024 | -2.91 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Sep 30, 2024 | -8.63 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Jun 30, 2024 | 2.73 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Mar 31, 2024 | -4.96 Mn |
| Dec 31, 2023 | -3.93 Mn |
| Dec 31, 2023 | -3.93 Mn |